-
Product Insights
NewSubacute Cutaneous Lupus Erythematosus (SCLE) – Drugs In Development, 2024
Empower your strategies with our Subacute Cutaneous Lupus Erythematosus (SCLE) – Drugs In Development, 2024 report and make more profitable business decisions. Subacute cutaneous lupus (SCLE) is an autoimmune disorder, that occurs when the immune system attacks itself. This is a subtype of CLE presenting as symmetric, non-scarring photosensitive erythematous rash usually over syn-exposed areas like face, neck, arms, upper back, and shoulders that causes skin rashes or lesions (sores). The Subacute Cutaneous Lupus Erythematosus (SCLE) drugs in development market research...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MP-0310 in Cervical Cancer Drug Details: MP-0310 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6289 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6289 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RG-6289 in Alzheimer's DiseaseDrug Details:RG-6289 is under development for the treatment of Alzheimer's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mocravimod Hydrochloride in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mocravimod Hydrochloride in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mocravimod Hydrochloride in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CMN-005 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CMN-005 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CMN-005 in B-Cell Acute Lymphocytic...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – mocravimod
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry mocravimod Drug Details KRP-203 is under development for the treatment of the autoimmune diseases...